Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ethical Drug Sales Down 0.3% in June: Crecon Report
August 8, 2012
- Hospira Files Additional Indication for Precedex for Non-Intubated Patients
August 8, 2012
- Daiichi Sankyo to Strengthen Cardiovascular Field by Comarketing Diabetes Treatments, Focusing on SGLT-2 Inhibitor
August 8, 2012
- 6 Listed Wholesalers Post Low Price Settlement Rates as of End-June, Showing Declines Compared to 2 Years Earlier
August 7, 2012
- Astellas to Close US Subsidiary for Urology Research
August 7, 2012
- Fuji Pharma to Acquire Thailand’s Largest Contract Manufacturer, to Make It Base of Overseas Operations
August 7, 2012
- Japan BCG Laboratory, Nippon Kayaku to Copromote Immunobladder
August 7, 2012
- Astellas to “Seek Every Opportunity” for Domestic Vaccine Business, Including Alliances with Foreign Companies
August 6, 2012
- Astellas’s Sales Down 3.3% in April-June Due to Competition with Generics
August 6, 2012
- Takeda to Exclusively Distribute 7 J&J OTC Brands in Japan
August 6, 2012
- Eisai’s April-June Sales, Profits Show Double-Digit Decrease by NHI Price Reduction of Aricept
August 6, 2012
- Sanofi Pasteur Not Planning to Follow Request to Cut IPV Price: President Triomphe
August 3, 2012
- Eisai: Domestic Sales of Aricept Down 6% on Volume Basis, to Target 90 Billion Yen through Patient Campaign
August 3, 2012
- Shionogi Files NDA for Lipodystrophy Treatment based on Data from Investigator-Initiated Trial
August 3, 2012
- DSP to Establish Sales Force for Anticancer Drugs in North America
August 3, 2012
- Rebamipide Is Most Frequently Prescribed Drug by Generic Name: Apollo Medical Survey
August 3, 2012
- Daiichi Sankyo: April-June Nexium Sales 6% of Full-Year Target, Set to Boost Promotion after Lifting of Long-Term Prescription Ban
August 2, 2012
- Otsuka Files for Additional Indication for Samsca for Fluid Retention with Liver Cirrhosis
August 2, 2012
- BMKK, Pfizer Promote Disease Education on Chronic Hepatitis B
August 2, 2012
- Shionogi Launches Endoxan Powder Aimed at Pediatric Patients
August 2, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…